The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

doi:10.1210/ENDO-100-6-1684

Paper

The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

Published Jun 1, 1977 · Angela Brodie, W. C. Schwarzel, A. A. Shaikh

Endocrinology

Q1 SJR score

366

Citations

5

Influential Citations

Full textSemantic Scholar

Abstract

4-Hydroxy-f-androstene-3,17-dione (4-OH-A) when tested at various concentrations was found to inhibit markedly the conversion of 4-andorstene-3,17-dione to estrogens inhuman placental and rat ovarian microsomes. To obtain evidence that estrogen biosynthesis could also be reduced in vivo with 4-OH-A, rats were treated sc at a dose level of 50 mg/kg body weight. After 3 h the ovarian veins were cannulated and blood collected. Estradiol concentrations in the plasma were reduced by 80% compared to control values during the proestrous surge and on Day 4 of pregnancy. 4-OH-A was also found to be effective in controlling estrogen-dependent reproductive and neoplastic processes. In rats treated from Day 2-7 of pregnancy, implantation of fertilized ova was completely prevented in some rats, while in others either implantation was delayed or the development of implants was retarded. 4-OH-A treatment of rats having estrogen-dependent breast tumors induced by 7,12-dimethylbenz(a)anthracene caused 80% of the tumors to regress significantly in 4 weeks of treatment; 42% of these regressed completely.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

4-OH-A effectively reduces estrogen-dependent reproductive and neoplastic processes, potentially preventing pregnancy and causing tumor regression in estrogen-dependent breast cancer.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

Sign up to use Study Snapshot

References

Citations

Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells

T6I-29, a novel SERM, effectively targets Y537S ER breast cancer cells by downregulating DKK1, a key oncogenic protein in ER+ breast cancers.

Maternal recognition of pregnancy in the pig: A servomechanism involving sex steroids, cytokines and prostaglandins.

Maternal recognition of pregnancy in pigs involves a complex servomechanism involving sex steroids, cytokines, and prostaglandins, rather than just conceptus estrogen and prostaglandin E2.

Targeting the formation of estrogens for treatment of hormone dependent diseases–current status

Current hormonal drugs for hormone-dependent diseases target local estrogen formation, with potential for combined treatments targeting multiple enzymes or different therapeutic mechanisms.

Delayed implantation induced by letrozole in mice

Letrozole-induced delayed implantation in mice can be used to study the effects of embryo implantation delay on late pregnancy events.

A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.

Heterocyclic compounds show promising structural-activity relationships towards aromatase, aiding in the design of potent aromatase inhibitors for breast cancer treatment.

Mechanisms of endocrine therapy resistance in breast cancer

Endocrine therapy resistance in breast cancer is driven by complex tumor microenvironment changes, and future therapeutic maneuvers may address this resistance.

Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment

Exemestane, Anastrozole, and Letrozole show significant binding interactions with TOP-IIA, suggesting potential as broad-spectrum anticancer drugs.

Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.

Highly selective cytochrome P450 inhibitors can be developed by weakening heme-binding group interactions, reducing molecular lipophilicity, and introducing small structural changes within compounds.

The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs

Formestane and Exemestane effectively inhibit breast cancer cell proliferation and can stop DMBA tumor growth, offering a new avenue for neodjuvant treatment.